Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared to placebo. The study showed cemiplimab reduced locoregional and distant ...

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer. Oral selective estrogen receptor degraders (SERDs) have become ...

Active surveillance (AS) appears to be a durable and safe long-term management strategy for patients with small, low-risk papillary thyroid cancer (PTC), with durability and age strongly correlated, ...

In recognition of October as Breast Cancer Awareness Month, Sarah Premji, MD, assistant director of Breast Cancer Research at Sarah Cannon Research Institute (SCRI), discusses exciting advancements in ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), according to ...

NBTXR3 combined with radiotherapy and ICIs showed a 47.4% objective response rate and 78.9% disease control rate in melanoma patients. A direct relationship was observed between local tumor response ...

Harpreet Singh, MD, former Director of the Division of Oncology 2 at the FDA, noted the importance of considering the global regulatory environment in the development of radiopharmaceuticals. This is ...

Cintredekin besudotox targets IL-12 alpha-2 receptor-expressing tumor cells, using convection-enhanced delivery to bypass the blood-brain barrier for glioblastoma treatment. Orphan drug designation ...

Casdatifan activates hundreds of genes in response to low oxygen levels, and when oxygen levels return to normal, HIF-2a is turned off. In patients with ccRCC, HIF-2a remains activated in the presence ...